N
SRNE

Natixis’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Natixis’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,147
Closed -$60K – 1405
2022
Q3 		$60K Buy
37,147
+22,147
+148% +$50.2K ﹤0.01% 1005
2022
Q2 		$30K Sell
15,000
-42,830
-74% -$74.1K ﹤0.01% 1082
2022
Q1 		$135K Buy
57,830
+42,100
+268% +$131K ﹤0.01% 1118
2021
Q4 		$73K Buy
+15,730
New +$97.7K ﹤0.01% 1194
2021
Q2 		– Sell
-10,700
Closed -$88K – 1175
2021
Q1 		$88K Sell
10,700
-301,100
-97% -$3.18M ﹤0.01% 1043
2020
Q4 		$2.13M Buy
311,800
+263,040
+539% +$2.11M 0.01% 674
2020
Q3 		$544K Buy
+48,760
New +$446K ﹤0.01% 598

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM